TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04616430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical endoxifen
Description: topical solution
Study: NCT04080414

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based high-intensity interval training
Description: Participants will be instructed to complete four, high-intensity interval training workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-based moderate-intensity continuous exercise
Description: Participants will be instructed to complete five, moderate-intensity continuous exercise workouts per week at home, for the duration of the 12-week trial. Participants will be provided with detailed instructions on how to complete each workout.
Study: NCT02315599

Intervention type: DRUG
Intervention: anti-CD19 CAR
Study: NCT04616430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical
Study: NCT00824512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGb 761 120 mg
Description: EGb 761® 120 mg bid, orally for 12 to 14 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 1 tablet BID, orally for 12 to 14 weeks
Study: NCT01064713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesetaxel
Description: Cohort A: 40 mg by mouth every 21 days.~Cohort B. 50 mg by mouth every 21 days.
Study: NCT03069547

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Exercise program
Description: The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details can be requested rom the responsible party. In brief the QE-program consists of:~- A short warm-up and 3 specific exercises for the quadriceps muscle~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Exercise program
Description: The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.~The program details be requested rom the responsible party. In brief the HE-program consists of:~- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles~Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc.
Study: NCT02677467

Intervention type: BIOLOGICAL
Intervention: Blood-pressure variability
Description: Day to Night Blood pressure variability

Intervention type: BIOLOGICAL
Intervention: Blood-pressure variability
Description: Day to Night Blood pressure variability
Study: NCT02310061

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-vascular lung water measurements by ultrasound (LW-US)
Description: It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard protocol of fluid management in hemodialysis
Description: The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
Study: NCT02305160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butantan
Description: Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
Study: NCT02227446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin antibiotic powder
Description: At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
Study: NCT03259360

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POP:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TSP:
Description: 90 days of Facebook messaging, weekly live sessions targeting tobacco use
Study: NCT04571255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music-Assisted Relaxation
Description: The music therapy sessions are based on MAR (Music-Assisted Relaxation), a music therapy technique that includes listening to live music, combined with deep diaphragmatic breathing and/or guided imagery relaxation. In a first step, the procedure will explained to the patient and he/she will be asked to close his/her eyes or focus on a fixed point on the ceiling or wall. Subsequently, a verbal introduction will be provided for fostering body and respiratory awareness. Then a mental image will be introduced (e.g., sitting on a beach watching the waves of the sea; being on top of a mountain looking at the horizon; imagining a safe and comfortable personalized place) and live music will be provided based on the principles of entrainment. The patient is asked to let himself/herself guide by the music and breath with the music while concentrating on the imagery. Once the music is over, the patient is again asked to become aware and the experience during the session will verbally discussed.
Study: NCT01747746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin

Intervention type: DRUG
Group type: OTHER
Intervention: Warfarin and Enoxaparin
Description: Historical Control
Study: NCT01970800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone
Description: Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
Study: NCT04110379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: All the dental procedures that will be done will be explained to the child using tell-show-do technique. VR glasses will be introduced to the child using tell-show-do technique and he will be given a choice of cartoon episodes to select from according to his own interest and age appropriate to view during the dental treatment. The child will be given five minutes to get familiar with the VR glasses before starting the dental treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Behavior Management Techniques
Description: Conventional behavior management techniques will be done to relieve the child's dental anxiety during the dental treatment such as : tell-show-do technique, distraction, and positive reinforcement, according to the child's behavior.
Study: NCT04716075

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib 2x100 MG Oral Capsule + alloSCT
Description: Acalabrutinib 100 mg caps will be administered twice daily for 3-6 months before the intended alloSCT. After restarting acalabrutinib (2x100 mg daily) after the transplant procedure it will be administered for further 9 months. In patients who do not have an acceptable donor acalabrutinib will be administered until disease progression or unacceptable toxicity.
Study: NCT04940559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Tablet
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Tablet
Description: Oral tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Tablet
Description: Oral tablet.
Study: NCT01429753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advanced Imaging Guided LV lead placement
Description: Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard LV lead placement
Description: Standard LV lead placement not guided by advanced imaging
Study: NCT02307396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ziprasidone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benperidol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benperidol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluspirilene
Study: NCT06102733

Intervention type: BEHAVIORAL
Intervention: Rehabilitation therapy
Description: Chronic pain rehabilitation therapy
Study: NCT02268461

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation
Description: Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
Study: NCT01557257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone block
Description: Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
Study: NCT01667224

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Actiponin
Description: The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amount and calorie of placebo are same with Actiponin.
Study: NCT01050920

Intervention type: BIOLOGICAL
Intervention: Blood collection
Study: NCT03242564

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vevazz LED
Description: Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
Study: NCT01630928

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal sympathetic denervation
Description: This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
Study: NCT01942161

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Low (2 mg/day)
Description: administered 2 mg once daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole Mid (6 - 12 mg/day)
Description: administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole High (24 - 30 mg/day)
Description: administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
Study: NCT00072930

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-522
Description: IV at a concentration of 50 mg/mL and 10mL vials

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Docetaxel + Prednisone* + Zoledronic Acid
Description: IV 75 mg/m2 IV 3-4 mg 5 mg
Study: NCT02555813

Intervention type: DRUG
Intervention: Abraxane
Description: Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity

Intervention type: DRUG
Intervention: Gemcitabine
Description: Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity
Study: NCT02186379

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RePace Intervention
Description: The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Control
Description: Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters.
Study: NCT04036474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Education Program
Description: The SPEP consisted of three lessons and each lesson took one to two hours to be implemented. SPEP was conducted through direct and indirect method. Direct method was conducted through lectures, question and answer, role play and educational videos. The tools used were video projectors and Power Point presentations. On the other hand, the indirect method was done through distributing of badge buttons and fridge magnets Be Free from Smoking. This method brought a simple message to increase awareness among adolescents to prevent smoking uptake. All instruments and protocols in this intervention were pilot tested to confirm feasibility and cultural appropriateness.
Study: NCT00760435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg IV over 2 hours once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (same volume as active drug)
Study: NCT04245670

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Body Radiotherapy (SABR) 35-50 Gy/5
Description: Stereotactic Ablative Body Radiotherapy (SABR) given in 5 weekly fractions. Simultaneously treating the pelvic lymph nodes, prostate and MRI-nodule to a total dose of 25 Gy, 35 Gy and up to 50 Gy, respectively. The radiation will be given with 6-18 months of ADT.
Study: NCT02969291

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reduced Sedentary Time Intervention (RSTI)
Description: Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
Study: NCT01023555

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1cc of blood in a single aerobic culture bottle
Description: The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
Study: NCT04245267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DIABEMPIC
Description: Patients are attended by 9 diabetes health-care professionals every 2 weeks for 5 months in a shared medical appointment scheme, including individual and group sessions. Patients will be evaluated at the end of the program and 1 year after.
Study: NCT01289353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV, weekly for 6 weeks, AUC of 2.0

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-RT or IMRT
Description: From week 2 to week 4 in the 6-week Carboplatin treatment:~Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy
Study: NCT00538967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 2 weeks once daily
Study: NCT00071513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAST-T/HSTS
Description: Skills training small group.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Intervention
Description: Assessment of needs and referral to services as needed.
Study: NCT03274505

Intervention type: OTHER
Intervention: Questionnaires
Description: * Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)

Intervention type: OTHER
Intervention: Questionnaires
Description: * Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)~* Clinical evaluation~* Routine neuropsychological evaluation (for stroke patients)~* Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) \> 10)
Study: NCT00439660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rotavirus Vaccine 116E Live Attenuated

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral Rotavirus Vaccine 116E Live Attenuated
Study: NCT00349804

Intervention type: OTHER
Group type: OTHER
Intervention: cool dry air
Description: cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
Study: NCT02365090

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: patching
Description: covering the sound eye with a patch to force use of the amblyopic eye

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: binocular games
Description: playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
Study: NCT01214629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125 milligrams per meter square per day (mg/m²/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2523355
Description: Administered intravenously as a 1-hour infusion on Days 1, 2, 3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4 mg/m²/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: 6 milligrams (mg) administered subcutaneously on Day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
Study: NCT00538967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 2 weeks once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: 2 weeks once daily
Study: NCT00138203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01958008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 high dose b.i.d.
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 low dose b.i.d.
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 high dose b.i.d.
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BI 113608 medium dose b.i.d.
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 low dose b.i.d.
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608 medium dose b.i.d.
Description: Film-coated tablet
Study: NCT03020199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab (AIN457) 300 mg was administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose was provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe was labeled as AIN457 150 mg/1 mL.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: nb-UVB
Description: Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application was performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face was recommended
Study: NCT03674996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same day discharge
Description: Discharge of the patient 12 hours after the minimally invasive radical prostatectomy - experimental group
Study: NCT04940559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Softgel
Description: Oral softgel capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - Softgel
Description: Oral softgel capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - LFC
Description: Oral LFC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danicopan - LFC
Description: Oral LFC.